MSB 2.75% $1.06 mesoblast limited

Time is coming, page-158

  1. 6,873 Posts.
    lightbulb Created with Sketch. 1267
    I think the SP is where it is because the market doesn't believe MSB is close to FDA approval.

    Dementia? The SP or you?

    I remember a time when the SP was over $5 and ol' Pledge himself made comments like 'there is no way the FDA won't approve aGVHD and save the kids!'. I was reminded by my misguided statements recently by a M.R. called Hector.

    Who's responsible for creating the market sentiment? The FDA, really?

    Hmmmmm, let's think about that for a moment..............? Who could be responsible for the market sentiment of a publicly listed company, I wonder....?

    Now the FDA are responsible for the MSB trials - that's a given! They are FDA trials, after all! The name says it all!
    And the assay requirements not being met in the process of FDA approval, even though it was spelt out prior to the P3 - that's on the FDA as well - I mean.........I just mean, yeah, that's the FDA screwing it up again. Bloody FDA - how dare they do their job correctly.
    And the guy charged with running the whole shooting match - it can't be him. It just can't be him. Because. Because people on here are either him or paid by him to say it isn't him, no matter what.

    The market has been spot on so far!

    You are confusing dementia with actually remembering what has happened. That's insane.

    You've got dementia. If you are reading this, you have already forgotten what this post was about.

    Time for a nap, SI. A 'momentous' nap. Sleep for 'weeks'.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.06
Change
-0.030(2.75%)
Mkt cap ! $1.235B
Open High Low Value Volume
$1.10 $1.10 $1.06 $1.830M 1.709M

Buyers (Bids)

No. Vol. Price($)
13 79080 $1.06
 

Sellers (Offers)

Price($) Vol. No.
$1.07 259232 18
View Market Depth
Last trade - 11.10am 20/06/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.